M. J. Van Der Moore

M. J. Van Der Moore's AcademicInfluence.com Rankings

M. J. Van Der Moore

Philosophy

#7654

World Rank

#10895

Historical Rank

Logic

#4700

World Rank

#6021

Historical Rank

philosophy Degrees

Download Badge

Philosophy

M. J. Van Der Moore's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is M. J. Van Der Moore Influential?

(Suggest an Edit or Addition)

(See a Problem?)

M. J. Van Der Moore's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (1997) (5587)
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. (2013) (4662)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. (2007) (3726)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. (2008) (3471)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. (2000) (2532)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. (2003) (2023)
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. (2000) (1970)
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. (1996) (1595)
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. (2010) (1235)
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (2014) (1129)
Cetuximab for the treatment of colorectal cancer. (2007) (1100)
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. (2006) (883)
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer (2005) (799)
Advanced pancreatic carcinoma: current treatment and future challenges (2010) (747)
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. (2009) (620)
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. (1996) (581)
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. (2008) (543)
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. (2012) (480)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. (2012) (471)
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. (2011) (399)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. (2007) (392)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. (2003) (370)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial (2017) (327)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers (2014) (314)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. (2015) (296)
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. (2005) (289)
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. (2014) (273)
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. (2015) (271)
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. (1997) (265)
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. (2003) (256)
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. (1999) (223)
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma (2017) (205)
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. (2005) (197)
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials (2009) (196)
Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. (2010) (190)
Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer (2006) (185)
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer (2006) (173)
A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer (2013) (171)
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. (2001) (167)
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. (1994) (160)
How expert physicians would wish to be treated if they had genitourinary cancer. (1988) (159)
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer (2010) (152)
PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 (2013) (143)
The contribution of attachment security and social support to depressive symptoms in patients with metastatic cancer (2007) (138)
Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). (2013) (136)
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. (2009) (132)
Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. (1997) (130)
Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience (2012) (129)
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. (2015) (122)
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. (2018) (122)
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. (2013) (121)
Canadian consensus guidelines for the management of testicular germ cell cancer. (2013) (115)
High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. (1998) (113)
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. (2006) (112)
Predictors of referral for specialized psychosocial oncology care in patients with metastatic cancer: the contributions of age, distress, and marital status. (2009) (112)
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. (2006) (111)
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. (2013) (111)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. (2015) (110)
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. (2009) (110)
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. (2006) (106)
Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review (1996) (106)
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. (2012) (104)
Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. (2007) (104)
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. (2005) (103)
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer (2008) (103)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (101)
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. (2011) (99)
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. (2011) (95)
Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks (2003) (93)
AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. (2011) (88)
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma (2018) (87)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma (2019) (86)
Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer (2019) (86)
Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer (2006) (85)
Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. (2014) (85)
The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. (1998) (84)
Alternate Endpoints for Screening Phase II Studies (2009) (83)
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. (1998) (82)
A review of erlotinib and its clinical use (2006) (81)
A Phase 2 study of perifosine in advanced or metastatic breast cancer (2008) (80)
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium (2011) (79)
Randomized phase II trials: inevitable or inadvisable? (2010) (77)
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. (2004) (75)
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer (2013) (71)
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) (2013) (70)
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. (2002) (69)
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. (2004) (68)
A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer (2010) (67)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (66)
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer (2012) (65)
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. (2012) (63)
Epidermal growth factor receptor expression in anal canal carcinoma. (2005) (63)
Neuroendocrine Tumors of the Gastrointestinal Tract: A Decade of Experience at the Princess Margaret Hospital (2008) (62)
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. (2002) (62)
Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. (2008) (60)
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial (2002) (58)
A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer (2005) (58)
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP) (2016) (55)
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. (2005) (54)
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma (2005) (53)
Therapeutic Drug Monitoring in Oncology (1987) (53)
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. (2014) (53)
Brief communication: a new combination in the treatment of advanced pancreatic cancer. (2005) (53)
A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (2008) (53)
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. (2010) (52)
Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. (2006) (52)
A Phase II study of oxaliplatin in urothelial cancer. (2005) (51)
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer (2012) (51)
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. (2005) (50)
Sorafenib for Metastatic Renal Cancer: The Princess Margaret Experience (2008) (49)
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. (2005) (48)
Maintenance of progesterone-facilitated sexual behavior in female rats requires continued hypothalamic protein synthesis and nuclear progestin receptor occupation. (1987) (47)
Validation of the short-form McGill pain questionnaire-2 in younger and older people with cancer pain. (2014) (47)
Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. (2015) (46)
Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin. (1998) (46)
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. (2013) (45)
PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). (2014) (44)
Treatment of hormone refractory prostate cancer. (2001) (44)
Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. (2007) (44)
Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). (2014) (43)
The communal coping model and cancer pain: the roles of catastrophizing and attachment style. (2012) (43)
Use of mesna to prevent ifosfamide-induced urotoxicity (1998) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. (2013) (41)
Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy (2013) (41)
High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC). (2016) (40)
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience (2016) (40)
Outcome of Adjuvant Therapy in Biliary Tract Cancers (2015) (39)
Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial (2008) (39)
No role for routine chest radiography in stage I seminoma surveillance. (2010) (39)
Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent (2009) (38)
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium (2008) (38)
Should surveillance be considered the standard of care in stage I seminoma (2005) (37)
Prostate cancer: 9. Treatment of advanced disease. (1999) (37)
Exome-Wide Association Study of Pancreatic Cancer Risk. (2017) (37)
Impact of opening an acute palliative care unit on administrative outcomes for a general oncology ward (2008) (37)
Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination (2006) (37)
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study (2014) (36)
A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. (1993) (36)
Determination of Lovastatin in Human Plasma Using Reverse-Phase High-Performance Liquid Chromatography With UV Detection (2000) (35)
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) (2008) (34)
Utility of serum tumor markers during surveillance for stage I seminoma (2012) (34)
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. (2014) (34)
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours (2005) (34)
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? (2007) (33)
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia (2006) (32)
Short report: Multicenter phase II trial of brequinar sodium in patients with advanced melanoma (1992) (32)
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining (2011) (31)
Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. (2013) (31)
Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days (2004) (31)
Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. (1998) (30)
Development of quality indicators of care for patients undergoing hepatic resection for metastatic colorectal cancer using a Delphi process. (2009) (29)
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium (2013) (29)
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer (2012) (27)
99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. (1999) (26)
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. (1998) (26)
Neoadjuvant treatment for pancreatic cancer--a review. (2008) (26)
Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. (2005) (26)
In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors. (2000) (25)
Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer (2013) (24)
Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. (2012) (24)
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. (2000) (24)
Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT) (2007) (23)
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). (2012) (23)
Unresectable Pancreatic Cancer (2011) (23)
Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. (2012) (23)
Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer (2004) (23)
Development and Validation of a Limited Sampling Strategy for 5‐Fluorouracil Given by Bolus Intravenous Administration (1993) (23)
Comparison of 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function (2001) (23)
Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. (2007) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer (2011) (22)
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer (2012) (21)
Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium (2005) (21)
Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. (2003) (21)
Quality of life in patients with K‐RAS wild‐type colorectal cancer (2014) (21)
The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3 (2007) (21)
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience (2017) (20)
Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. (2019) (20)
Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. (2013) (20)
Depression and use of health care services in patients with advanced cancer. (2013) (20)
A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. (2012) (20)
A phase II study of Temozolomide in advanced untreated pancreatic cancer (2004) (19)
Appropriate radiation volume for stage IIA/B testicular seminoma. (2003) (19)
HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. (2013) (19)
Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium (2007) (19)
A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97 (1994) (19)
Cluster-randomized trial of early palliative care for patients with metastatic cancer. (2012) (18)
Phase II trial of erlotinib in advanced pancreatic cancer (PC). (2016) (18)
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. (2002) (18)
Clinical Pharmacokinetics of Cyclophosphamide (1991) (18)
Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. (2005) (18)
Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment. (2011) (17)
A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (2011) (17)
A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. (2004) (17)
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over (2009) (17)
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer (2016) (16)
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium (2009) (16)
Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial (2007) (16)
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial (2019) (16)
Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor. Case report. (1997) (14)
Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue (2006) (14)
Impact of Granulocyte‐colony Stimulating Factor on Bleomycin‐induced Pneumonitis in Chemotherapy‐treated Germ Cell Tumors (2017) (14)
A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3 (2016) (12)
Benefits of platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series. (2012) (12)
Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors (2009) (11)
Survival Following Resection of Intra- and Extra-Hepatic Metastases from Colorectal Cancer: A Phase II Trial (2016) (11)
Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. (2019) (11)
A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] Phase II Consortium (2005) (11)
Erratum: DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy (Journal of the National Cancer Institute (2011) 103:11 (863-875)) (2011) (10)
Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series. (2012) (10)
Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study (1990) (10)
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. (2011) (10)
Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial (2020) (10)
43 Issues in the management of stage I testicular seminoma (1997) (9)
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer (2012) (9)
Surveillance is an appropriate management strategy in patients with stage I seminoma (2002) (9)
A case of small bowel obstruction due to intraluminal metastases from metastatic renal cell cancer. (2008) (9)
NCIC CTG IND 103: a Phase I and pharmacokinetic (PK) study of the novel L-nucleoside analog troxacitabine (BCH-4556) given every 21 days (1999) (9)
Overview of Canadian trials in hormonally resistant prostate cancer. (1996) (8)
Models of care in outpatient cancer centers. (2012) (8)
Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. (2012) (8)
Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. (2009) (8)
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathological complete response, local recurrence free survival &disease free survival (2004) (8)
Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC). (2013) (8)
Do Correlates of Pain-Related Stoicism and Cautiousness Differ in Younger and Older People With Advanced Cancer? (2017) (7)
Latency and interval therapy affect the evolution in metastatic colorectal cancer (2020) (7)
The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer: 101 (1994) (7)
Metformin for pancreatic cancer. (2015) (7)
Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women (1999) (7)
A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (mCRC) (2008) (7)
The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. (2011) (6)
Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial (2012) (6)
Pancreatic cancer: what the oncologist can offer for palliation. (2002) (6)
The relationship between the development of rash and clinical and quality of life outcomes by Kras mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. (2011) (6)
Use of radiotherapy for seminoma patients with low-volume infradiaphragmatic nodal disease. (2013) (6)
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours (2013) (6)
A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner (2004) (5)
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis. (2012) (5)
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. (2013) (5)
Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS). (2015) (5)
A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. (2009) (5)
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. (1996) (5)
A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer. (1993) (5)
A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial (2008) (4)
A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial. (2011) (4)
Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers. (2013) (4)
Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): A large multicenter study. (2013) (4)
Screening for pancreatic cancer in a high-risk cohort: A 7-year experience. (2011) (4)
Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). (2013) (4)
The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17 (2008) (4)
Next-generation sequencing: Profiling gallbladder cancer (GBC). (2015) (4)
Total treatment burden in stage I seminoma patients. (2010) (4)
A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3. (2014) (4)
Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. (2011) (4)
Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial. (2015) (4)
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC). (2006) (4)
Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum (2004) (4)
The treatment of advanced pancreatic cancer: current evidence and future challenges. (2008) (4)
Targeting metastatic prostate cancer: the search for innovative systemic therapies. (2006) (3)
Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. (2013) (3)
A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. (1995) (3)
Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial. (2019) (3)
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET). (2009) (3)
BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17. (2012) (3)
Reply to D.J. Stewart (2010) (3)
Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors (2005) (3)
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours (2003) (3)
Novel targets in prostate cancer (2006) (3)
Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian Testicular Cancer Survivors (TCS). (2015) (3)
Eyelid metastasis from mediastinal teratoma with malignant transformation (2007) (3)
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib. (2014) (3)
A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS). (2013) (2)
Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer (2006) (2)
From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). (2013) (2)
Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657). (2018) (2)
The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. (2011) (2)
UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRA CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer (2006) (2)
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022) (2)
Evaluation of low-dose CT scans for surveillance in stage I testicular cancer. (2011) (2)
A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). (2012) (2)
Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience. (2014) (2)
Problems Associated with the Assessment of Patients with Metastatic Breast Cancer: Can Past Experience Teach us to do Better Clinical Trials? (1987) (2)
Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. (2013) (2)
Contemporary Management of Stage I and Stage II Seminoma (2013) (2)
Cardiovascular disease (CVD) risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of U.S. and Canadian patients. (2015) (2)
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG) (2019) (2)
Analysis of clonal evolution in colorectal cancer. (2014) (2)
A phase II study of triapine in combination with gemcitabine in advanced pancreatic carcinoma: A Princess Margaret Hospital Phase II Consortium Trial (2005) (2)
Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone. (2010) (2)
AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium. (2007) (2)
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer. (1998) (2)
When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer (2007) (2)
Psychometric Evaluation of the Pain Attitudes Questionnaire-Revised for People With Advanced Cancer. (2017) (2)
Age differences in cancer pain: a pilot study (2004) (1)
Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: Time to write the obituary? (2012) (1)
FOLFIRINOX for advanced pancreatic cancer: The Princess Margaret experience. (2015) (1)
Other chemotherapy regimens including mitoxantrone and suramin. (1997) (1)
Physical and psychological well-being in patients with stage IV GI cancer. (2004) (1)
Abstract 12: Germline BRCA mutations in an unselected cohort of patients with pancreatic adenocarcinoma (2014) (1)
49 Prognostic factors in stage I seminoma managed by surveillance (1995) (1)
1 DISTINCT MUTATIONAL SIGNATURES ARE ASSOCIATED WITH CORRELATES OF 1 INCREASED IMMUNE ACTIVITY IN PANCREATIC DUCTAL ADENOCARCINOMA 2 3 (2016) (1)
Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review (1)
Quality of life (QoL) assessment in patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or placebo: Results of the NCIC Clinical Trials Group and AGITG CO.20 trial. (2012) (1)
A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC). (2016) (1)
Quality of life in advanced prostate cancer. (1997) (1)
A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial. (2012) (1)
Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer. (2011) (1)
Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo). (2012) (1)
Long-term effects of conservation therapy for muscle invasive bladder carcinoma. (2004) (1)
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory colorectal carcinoma. (2009) (1)
nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). (2015) (1)
Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. (2013) (1)
Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer (2006) (1)
Smoking status and treatment outcome in patients with pancreatic cancer. (2016) (0)
Late Relapse in Patients on Surveillance for Stage I Testicular Seminoma (1994) (0)
63 Primary and adjuvant chemoradiotherapy for locally advanced pancreatic cancer: A phase I/II study with long term outcome (2006) (0)
Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials. (2023) (0)
Abstract A24: Gene expression along the glycolysis-cholesterol synthesis axis and outcome in pancreatic cancer (2019) (0)
Predictive Biomarkers and Personalized Medicine PIK 3 CA , BRAF , andPTENStatus andBene fi t fromCetuximab in the Treatment of Advanced Colorectal Cancer — Results from NCIC CTG / AGITG CO . 17 (2014) (0)
Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'. (2013) (0)
Large retroperitoneal lymph nodes (RPLN) as a predictor for venous thromboembolism (VTE) in patients (pts) with germ cell tumor (GCT) receiving first-line chemotherapy (chemo). (2012) (0)
154 Toxicity and survival in adjuvant chemoradiotherapy in patients with resected gastric adenocarcinoma (2005) (0)
Erratum: A phase I study of combined radiation therapy with 5- fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma (International Journal of Radiation Oncology Biology (1996) 34 (445-450)) (1996) (0)
Original article Long-term outcome of radiation-based conservation therapy for invasive bladder cancer (2007) (0)
Evaluating the time toxicity of cancer treatment in the CCTG CO.17 randomized clinical trial (RCT). (2022) (0)
Treatment of metastatic bladder cancer in the elderly (1993) (0)
Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs) (2007) (0)
Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT). (2016) (0)
Major arterial resection for stage 3 adenocarcinoma of the pancreas. (2018) (0)
Toxicity and outcomes of adjuvant chemoradiotherapy in patients with resected gastric adenocarcinoma (2005) (0)
Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer. (2012) (0)
Outcome of adjuvant therapy for biliary tract cancers. (2012) (0)
Sorafenib for the treatment of metastatic renal cancer (MRC) in the real world: The Princess Margaret Hospital (PMH) experience (2007) (0)
Metastatic Renal Cell Cancer A Case of Small Bowel Obstruction Due to Intraluminal Metastases from (2008) (0)
Population pharmacokinetics of troxacitabine (2004) (0)
CTG / AGITG CO . 17 Results from NCIC − − Treatment of Advanced Colorectal Cancer , and PTEN Status and Benefit from Cetuximab in the PIK 3 CA , BRAF (2014) (0)
An analysis of the effect of smoking status on erlotinib pharmacokinetics (PKs), toxicity, and ability to dose escalate in a phase II study of erlotinib in advanced pancreatic cancer (PC). (2010) (0)
Toxicity, Survival and Predictors of Outcome in Patients Receiving Adjuvant Chemoradiation for Gastric Adenocarcinoma (2005) (0)
Surgical oncology: Is PBD suitable for resectable pancreatic cancer? (2010) (0)
A phase II study of doxorubicin and cyclosporin A in advanced colorectal cancer with in vivo measurement of P-glycoprotein.: 134 (1994) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Systemic Therapy of Bladder Cancer (2000) (0)
Prospective genomic/transcriptomic profiling of advanced pancreatic ductal adenocarcinoma (PDAC) for personalized therapy: Feasibility and preliminary results from the COMPASS study (NCT02750657). (2017) (0)
Periampullary Cancer ESPAC-3(v2) trial: a Randomised Controlled Phase III Trial of Adjuvant Chemotherapy Versus Observation in Patients With Periampullary Adenocarcinomas of the Head of the Pancreas (2011) (0)
Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada (2013) (0)
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC). (2012) (0)
Phase II trials (P2T) in advanced pancreatic cancer (APC): Systematic review with focus on the design, entry criteria, and endpoints used. (2010) (0)
Large retroperitoneal lymph nodes (RPLN) as a predictor for venous thromboembolism (VTE) in patients (pts) with germ cell tumor (GCT) receiving first-line chemotherapy (chemo). (2012) (0)
Chemotherapy in Hormone Refractory Prostate Cancer (2008) (0)
Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. (2006) (0)
Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo). (2012) (0)
Patients' perceptions of early palliative oncology care: A qualitative analysis. (2013) (0)
Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. (2018) (0)
Expanding the Role of EGFR Inhibitors in Prostate Cancer (2006) (0)
Prevalence of pathological features in advanced seminoma: Implications for managment of stage I disease. (2010) (0)
Large retroperitoneal lymph nodes (RPLN) as a novel risk factor for venous thromboembolism (VTE) in germ cell tumor (GCT) patients (pts) receiving first-line chemotherapy (chemo). (2012) (0)
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC). (2012) (0)
Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. (2023) (0)
Patients' and caregivers' views on the timing and benefits of early palliative care: A qualitative study. (2013) (0)
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance). (2018) (0)
A review of the patterns of docetaxel use for hormone refractory prostate cancer (HRPC) at the Princess Margaret Hospital. (2009) (0)
182 INTENSITY MODULATED RADIOTHERAPY (IMRT) AND CONCURRENT CHEMOTHERAPY (CHT) FOR ANAL AND PERIANAL CANCER: PRELIMINARY REPORT OF ACUTE TOXICITY (2009) (0)
Phase I/II study of combined modality therapy in pancreatic cancer with gemcitabine (Gem) and escalating dose radiation therapy (RT) (2001) (0)
Extended lymphadenectomy and adjuvant chemotherapy in muscle-invasive bladder cancer treated by radical cystectomy. (2012) (0)
Chemotherapy in Prostate Cancer (2005) (0)
Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma (2005) (0)
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC). (2011) (0)
P19. Comparison of sestamibi and doxorubicin for detection of multidrug resistance (2000) (0)
Should my accountant sing La Traviata at the Met? (2013) (0)
FOLFIRINOX for advanced pancreatic cancer (2016) (0)
ACCUMULATION OF SESTAMIBI IN DRUG-SELECTED AND GENETRANSFECTED MULTIDRUG RESISTANT BREAST CANCER CELL LINES (1998) (0)
155 Impact of surgical and pathological features on outcome in patients receiving adjuvant chemoradiation for gastric adenocarcinoma (2005) (0)
Counterpoint: Men should be treated for hormone refractory prostate cancer with systemic chemotherapy when they are symptomatic, and not before. (2003) (0)
Clinical outcomes of late relapse in stage I seminoma. (2015) (0)
A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).: PD6-1-7 (2007) (0)
Extended lymphadenectomy and adjuvant chemotherapy in muscle-invasive bladder cancer treated by radical cystectomy. (2012) (0)
to determine the success of these attempts to bring metformin into cancer therapy. (2015) (0)
An innovative approach to post-treatment cancer care: The After Cancer Treatment Transition Clinic (ACTT). (2012) (0)
Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study. (2011) (0)
Latency and interval therapy affect the evolution in metastatic colorectal cancer (2020) (0)
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. (1998) (0)
A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer. (2009) (0)
Gemcitabine with cisplatin has a better safety profile and similar survival rates as methotrexate, vinblastine, doxorubicin and cisplatin for those with advanced or metastatic bladder cancer (2001) (0)
(311) Acceptance of pain: A preliminary study in advanced cancer patients (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With M. J. Van Der Moore?

M. J. Van Der Moore is affiliated with the following schools:

Seoul National University
Aarhus University
University of Sydney
University of British Columbia
McMaster University
Queen's University at Kingston
University of Valencia
University of Toronto